

# Carol S Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633270/publications.pdf>

Version: 2024-02-01

40  
papers

1,147  
citations

430874

18  
h-index

395702

33  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. <i>Trends in Biotechnology</i> , 2022, 40, 875-890.	9.3	17
2	Advances in delivery vectors for gene therapy in liver cancer. <i>Therapeutic Delivery</i> , 2020, 11, 833-850.	2.2	18
3	p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy. <i>Molecular Pharmaceutics</i> , 2019, 16, 3386-3398.	4.6	15
4	Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53. <i>Journal of Ovarian Research</i> , 2019, 12, 45.	3.0	7
5	Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. <i>Journal of Ovarian Research</i> , 2019, 12, 38.	3.0	9
6	Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics. <i>Journal of Physical Chemistry B</i> , 2018, 122, 3864-3875.	2.6	11
7	Application of Thiol-ene/Thiol-ene Reactions for Peptide and Protein Macrocyclizations. <i>Chemistry - A European Journal</i> , 2017, 23, 7087-7092.	3.3	36
8	Delivery of drugs and macromolecules to the mitochondria for cancer therapy. <i>Journal of Controlled Release</i> , 2016, 240, 38-51.	9.9	101
9	Inhibition of Bcr-Abl in Human Leukemic Cells with a Coiled-Coil Protein Delivered by a Leukemia-Specific Cell-Penetrating Peptide. <i>Molecular Pharmaceutics</i> , 2015, 12, 1412-1421.	4.6	8
10	Resistant mutations in CML and Ph+ALL – role of ponatinib. <i>Biologics: Targets and Therapy</i> , 2014, 8, 243.	3.2	65
11	Delivery of a Monomeric p53 Subdomain with Mitochondrial Targeting Signals from Pro-Apoptotic Bak or Bax. <i>Pharmaceutical Research</i> , 2014, 31, 2503-2515.	3.5	15
12	Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity. <i>Molecular Pharmaceutics</i> , 2014, 11, 2442-2452.	4.6	7
13	Multidomain Targeting of Bcr-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML. <i>Molecular Pharmaceutics</i> , 2013, 10, 3475-3483.	4.6	12
14	The DNA Binding Domain of p53 Is Sufficient To Trigger a Potent Apoptotic Response at the Mitochondria. <i>Molecular Pharmaceutics</i> , 2013, 10, 3592-3602.	4.6	18
15	A Chimeric p53 Evades Mutant p53 Transdominant Inhibition in Cancer Cells. <i>Molecular Pharmaceutics</i> , 2013, 10, 3922-3933.	4.6	18
16	Controlled Access of p53 to the Nucleus Regulates Its Proteasomal Degradation by MDM2. <i>Molecular Pharmaceutics</i> , 2013, 10, 1340-1349.	4.6	14
17	A Single Mutant, A276S of p53, Turns the Switch to Apoptosis. <i>Molecular Pharmaceutics</i> , 2013, 10, 1350-1359.	4.6	10
18	Targeting malignant mitochondria with therapeutic peptides. <i>Therapeutic Delivery</i> , 2012, 3, 961-979.	2.2	39

#	ARTICLE	IF	CITATIONS
19	Utilizing the Estrogen Receptor Ligand-Binding Domain for Controlled Protein Translocation to the Insoluble Fraction. <i>Pharmaceutical Research</i> , 2012, 29, 3455-3463.	3.5	3
20	Direct Induction of Apoptosis Using an Optimal Mitochondrially Targeted p53. <i>Molecular Pharmaceutics</i> , 2012, 9, 1449-1458.	4.6	33
21	Improved Coiled-Coil Design Enhances Interaction with Bcr-Abl and Induces Apoptosis. <i>Molecular Pharmaceutics</i> , 2012, 9, 187-195.	4.6	23
22	Enhanced and Selective Killing of Chronic Myelogenous Leukemia Cells with an Engineered BCR-ABL Binding Protein and Imatinib. <i>Molecular Pharmaceutics</i> , 2012, 9, 3318-3329.	4.6	11
23	Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs. <i>Pharmaceutical Research</i> , 2012, 29, 1098-1109.	3.5	16
24	Selective Targeting of c-Abl via a Cryptic Mitochondrial Targeting Signal Activated by Cellular Redox Status in Leukemic and Breast Cancer Cells. <i>Pharmaceutical Research</i> , 2012, 29, 2317-2328.	3.5	10
25	The Androgen Receptor and Its Use in Biological Assays: Looking Toward Effect-Based Testing and Its Applications. <i>Journal of Analytical Toxicology</i> , 2011, 35, 594-607.	2.8	19
26	Disruption of Bcr-Abl Coiled Coil Oligomerization by Design. <i>Journal of Biological Chemistry</i> , 2011, 286, 27751-27760.	3.4	28
27	The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain. <i>BioTechniques</i> , 2010, 49, 519-524.	1.8	12
28	Controlling subcellular delivery to optimize therapeutic effect. <i>Therapeutic Delivery</i> , 2010, 1, 169-193.	2.2	45
29	Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. <i>Journal of Controlled Release</i> , 2009, 140, 245-249.	9.9	21
30	Optimizing the protein switch: Altering nuclear import and export signals, and ligand binding domain. <i>Journal of Controlled Release</i> , 2007, 120, 220-232.	9.9	24
31	Signal Sequences for Targeting of Gene Therapy Products to Subcellular Compartments: The Role Of CRM1 in Nucleocytoplasmic Shuttling of the Protein Switch. <i>Pharmaceutical Research</i> , 2007, 24, 2146-2155.	3.5	9
32	Geldanamycin, an inhibitor of Hsp90, Blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains. <i>AAPS Journal</i> , 2006, 8, E718-E728.	4.4	14
33	Controlling Protein Compartmentalization to Overcome Disease. <i>Pharmaceutical Research</i> , 2006, 24, 17-27.	3.5	55
34	Effect of Initial Subcellular Localization of Progesterone Receptor on Import Kinetics and Transcriptional Activity. <i>Molecular Pharmaceutics</i> , 2005, 2, 509-518.	4.6	20
35	Correlation among agonist dose, rate of import, and transcriptional activity of liganded progesterone receptor B isoform in living cells. <i>Pharmaceutical Research</i> , 2003, 20, 1574-1580.	3.5	7
36	Model system to study classical nuclear export signals. <i>AAPS PharmSci</i> , 2002, 4, 61-68.	1.3	24

#	ARTICLE	IF	CITATIONS
37	Trafficking of nuclear receptors in living cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 74, 249-254.	2.5	118
38	Differential Localization and Activity of the A- and B-Forms of the Human Progesterone Receptor Using Green Fluorescent Protein Chimeras. <i>Molecular Endocrinology</i> , 1999, 13, 366-375.	3.7	135
39	Intracellular localization and trafficking of steroid receptors. <i>Cell Biochemistry and Biophysics</i> , 1999, 31, 119-127.	1.8	46
40	Differential Localization and Activity of the A- and B-Forms of the Human Progesterone Receptor Using Green Fluorescent Protein Chimeras. <i>Molecular Endocrinology</i> , 1999, 13, 366-375.	3.7	38